Etheridge, M. L. et al. The big picture on nanomedicine: the state of investigational and approved nanomedicine products Nanomedicine9, 1–14 (2013).
Su, Y. L. & Hu, S. H. Functional nanoparticles for tumor penetration of therapeutics. Pharmaceutics10, 1–21 (2018).
Tran, S., DeGiovanni, P.-J., Piel, B. & Rai, P. Cancer nanomedicine: a review of recent success in drug delivery. Clin. Transl. Med.6, 44 (2017).
Hare, J. I. et al. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv. Drug Deliv. Rev.108, 25–38 (2017).
Strambeanu, N., Demetrovici, L., Dragos, D. & Lungu, M. in Nanoparticles’ Promises and Risks: Characterization, Manipulation, and Potential Hazards to Humanity and the Environment (eds Lungu, M., Neculae, A., Bunoiu, M. & Biris, C.) (Springer, 2015).
Roberts, W. G. & Palade, G. E. G. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci.108, 2369–2379 (1995).
Tong, R., Hemmati, H. D., Langer, R. & Kohane, D. S. Photoswitchable nanoparticles for triggered tissue penetration and drug delivery. J. Am. Chem. Soc.134, 8848–8855 (2012).
Kong, S. D. et al. Magnetically vectored nanocapsules for tumor penetration and remotely switchable on-demand drug release. Nano Lett.10, 5088–5092 (2010).
Wang, B. et al. Simultaneously overcome tumor vascular endothelium and extracellular matrix barriers via a non-destructive size-controlled nanomedicine. J. Control. Release268, 225–236 (2017).
Bazak, R. et al. Cancer active targeting by nanoparticles: a comprehensive review of literature. J. Cancer Res. Clin. Oncol.141, 769–784 (2015).
Hauert, S. & Bhatia, S. N. Mechanisms of cooperation in cancer nanomedicine: towards systems nanotechnology. Trends Biotechnol.32, 448–455 (2014).
Li, Y. et al. Cell and nanoparticle transport in tumour microvasculature: the role of size, shape and surface functionality of nanoparticles. Interface Focus6, 1–15 (2016).
Park, J.-H. et al. Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc. Natl Acad. Sci.107, 981–986 (2010).
Von Maltzahn, G. et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat. Mater.10, 545–552 (2011).
Fu, Y. et al. A feasible strategy for self-assembly of gold nanoparticles: via dithiol-PEG for photothermal therapy of cancers. RSC Adv.8, 6120–6124 (2018).
Xiao, Z. et al. DNA self-assembly of targeted near-infrared-responsive gold nanoparticles for cancer thermo-chemotherapy. Angew. Chem.—Int. Edn.51, 11853–11857 (2012).
Bae, Y. H. & Park, K. Targeted drug delivery to tumors: myths, reality and possibility. J. Control. Release153, 198–205 (2011).
Lookman, T., Balachandran, P. V., Xue, D. & Yuan, R. Active learning in materials science with emphasis on adaptive sampling using uncertainties for targeted design. npj Comput. Mater.5, 1–17 (2019).
Deisboeck, T. S., Zhang, L., Yoon, J. & Costa, J. In silico cancer modeling: is it ready for prime time? Nat. Clin. Practice Oncol.6, 34–42 (2009).
Michor, F. & Beal, K. Improving cancer treatment via mathematical modeling: surmounting the challenges is worth the effort. Cell163, 1059–1063 (2015).
Dogra, P. et al. Mathematical modeling in cancer nanomedicine: a review. Biomed. Microdevices21, 40 (2019).
Talmadge, J. E. & Fidler, I. J. The biology of cancer metastasis: historical perspective. Cancer Res.70, 5649–5669 (2010).
Siegel, R., Miller, K. D. & Ahmedin, J. Cancer Statistics, 2017. CA: Cancer J. Clinicians67, 7–30 (2017).
Chauviere, A. H. et al. Mathematical oncology: how are the mathematical and physical sciences contributing to the war on breast cancer? Curr. Breast Cancer Rep.2, 121–129 (2010).
Deisboeck, Z. & Yoon, C. In silico modelling—is it ready for prime time. Program6, 34–42 (2011).
Rejniak, K. A. & Anderson, A. R. Hybrid models of tumor growth. Wiley Interdisciplinary Rev.: Syst. Biol. Med.3, 115–125 (2011).
An, G. & Mi, Q. Agent based models in translational systems biology. Syst. Biol. Med.1, 159–171 (2009).
Deisboeck, T. S. & Stamatakos, G. S. Multiscale Cancer Modeling (CRC Press, 2010).
Norton, K.-A., Gong, C., Jamalian, S. & Popel, A. Multiscale agent-based and hybrid modeling of the tumor immune microenvironment. Processes7, 1–23 (2019).
Metzcar, J., Wang, Y., Heiland, R. & Macklin, P. A review of cell-based computational modeling in cancer biology. JCO Clin. Cancer Inform.3, 1–13 (2019).
Zhu, X., Zhou, X., Lewis, M. T., Xia, L. & Wong, S. Cancer stem cell, niche and EGFR decide tumor development and treatment response: a bio-computational simulation study. J. Theor. Biol.269, 138–49 (2011).
Sefidgar, M. et al. Numerical modeling of drug delivery in a dynamic solid tumor microvasculature. Microvascular Res.99, 43–56 (2015).
Grogan, J. A. et al. Microvessel chaste: an open library for spatial modeling of vascularized tissues. Biophys. J.112, 1767–1772 (2017).
Shah, P. N. et al. Extravasation of Brownian spheroidal nanoparticles through vascular pores. Biophys. J.115, 1103–1115 (2018).
Owen, M. R. et al. Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy. Cancer Res.71, 2826–2837 (2011).
Chou, C. Y., Huang, C. K., Lu, K. W., Horng, T. L. & Lin, W. L. Investigation of the spatiotemporal responses of nanoparticles in tumor tissues with a small-scale mathematical model. PLoS ONE8, e59135 (2013).
Nehoff, H., Parayath, N. N., Domanovitch, L., Taurin, S. & Greish, K. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. Int. J. Nanomed.9, 2539–55 (2014).
Chrastina, A., Massey, K. A. & Schnitzer, J. E. Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdisciplinary Rev.: Nanomed. Nanobiotechnol.3, 421–37 (2011).
Barua, S. & Mitragotri, S. Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects. Nano Today9, 223–243 (2014).
Curtis, L. T., England, C. G., Wu, M., Lowengrub, J. & Frieboes, H. B. An interdisciplinary computational/experimental approach to evaluate drug-loaded gold nanoparticle tumor cytotoxicity. Nanomedicine11, 197–216 (2016).
Shah, A. B., Rejniak, K. A. & Gevertz, J. L. Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases. Math. Biosci. Eng.13, 1185–1206 (2016).
Al-Obaidi, H. & Florence, A. T. Nanoparticle delivery and particle diffusion in confined and complex environments. J. Drug Deliv. Sci. Technol.30, 266–277 (2015).
Wang, Z. et al. Theory and experimental validation of a spatio-temporal model of chemotherapy transport to enhance tumor cell kill. PLoS Comput. Biol.12, e1004969 (2016).
Hamis, S., Nithiarasu, P. & Powathil, G. G. What does not kill a tumour may make it stronger: In silico insights into chemotherapeutic drug resistance. J. Theor. Biol.454, 253–267 (2018).
ming Ding, H. & qiang Ma, Y. Computer simulation of the role of protein corona in cellular delivery of nanoparticles. Biomaterials35, 8703–8710 (2014).
Zhang, S., Gao, H. & Bao, G. Physical principles of nanoparticle cellular endocytosis. ACS Nano9, 8655–8671 (2015).
Martinez-Veracoechea, F. J. & Frenkel, D. Designing super selectivity in multivalent nano-particle binding. Proc. Natl Acad. Sci.108, 10963–10968 (2011).
Pascal, J. et al. Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response. ACS Nano7, 11174–11182 (2013).
Angioletti-Uberti, S. Theory, simulations and the design of functionalized nanoparticles for biomedical applications: a soft matter perspective. npj Comput. Mater.3, 1–48 (2017).
Karolak, A., Markov, D. A., McCawley, L. J. & Rejniak, K. A. Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues. J. Roy. Soc. Interface15, 20170703 (2018).
Afonin, K. A. et al. In silico design and enzymatic synthesis of functional RNA nanoparticles. Acc. Chem. Res.47, 1731–1741 (2014).
Finley, S. D., Angelikopoulos, P., Koumoutsakos, P. & Popel, A. S. Pharmacokinetics of Anti-VEGF Agent aflibercept in cancer predicted by data-driven, molecular-detailed model. CPT: Pharmacometrics Syst. Pharmacol.4, 641–649 (2015).
Wang, Z., Bordas, V., Sagotsky, J. & Deisboeck, T. S. Identifying therapeutic targets in a combined EGFR-TGFβ R signalling cascade using a multiscale agent-based cancer model. Math. Med. Biol.29, 95–108 (2012).
Blanco, E., Shen, H. & Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnol.33, 9 (2015).
Longmire, M., Choyke, P. L. & Kobayashi, H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine3, 703–717 (2008).
Gustafson, H. H., Holt-Casper, D., Grainger, D. W. & Ghandehari, H. Nanoparticle uptake: the phagocyte problem. Nano Today10, 487–510 (2015).
Fedosov, D. A., Noguchi, H. & Gompper, G. Multiscale modeling of blood flow: from single cells to blood rheology. Biomech. Model. Mechanobiol.13, 239–258 (2014).
Lopez, H. & Lobaskin, V. Coarse-grained model of adsorption of blood plasma proteins onto nanoparticles. J. Chem. Phys.143, 12B620_1 (2015).
Shao, Q. & Hall, C. K. Protein adsorption on nanoparticles: model development using computer simulation. J. Phys.: Condens. Matter28, 414019 (2016).
Maleki, R. et al. ph-sensitive loading/releasing of doxorubicin using single-walled carbon nanotube and multi-walled carbon nanotube: a molecular dynamics study. Comput. Methods Programs Biomed.186, 105210 (2020).
Yoo, J.-W., Chambers, E. & Mitragotri, S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr. Pharm. Des.16, 2298–2307 (2010).
Müller, K., Fedosov, D. A. & Gompper, G. Margination of micro- and nano-particles in blood flow and its effect on drug delivery. Sci. Rep.4, 1–8 (2014).
Lin, Z., Monteiro-Riviere, N. A. & Riviere, J. E. A physiologically based pharmacokinetic model for polyethylene glycol-coated gold nanoparticles of different sizes in adult mice. Nanotoxicology10, 162–172 (2016).
Yuan, D., He, H., Wu, Y., Fan, J. & Cao, Y. Physiologically based pharmacokinetic modeling of nanoparticles. J. Pharm. Sci.108, 58–72 (2019).
Ding, H.-m & Ma, Y.-q Computational approaches to cell–nanomaterial interactions: keeping balance between therapeutic efficiency and cytotoxicity. Nanoscale Horizons3, 6–27 (2017).
Koumoutsakos, P., Pivkin, I. & Milde, F. The fluid mechanics of cancer and its therapy. Annu. Rev. Fluid Mech.45, 325–355 (2013).
Nakamura, Y., Mochida, A., Choyke, P. L. & Kobayashi, H. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjugate Chem.27, 2225–2238 (2016).
Björnmalm, M., Thurecht, K. J., Michael, M., Scott, A. M. & Caruso, F. Bridging bio-nano science and cancer nanomedicine. ACS Nano11, 9594–9613 (2017).
Nichols, J. W. & Bae, Y. H. Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today7, 606–618 (2012).
Fullstone, G., Wood, J., Holcombe, M. & Battaglia, G. Modelling the transport of nanoparticles under blood flow using an agent-based approach. Sci. Rep.5, 1–13 (2015).
Ferretti, S., Allegrini, P. R., Becquet, M. M. & McSheehy, P. M. Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics. Neoplasia11, 874–881 (2015).
Lameijer, M. A., Tang, J., Nahrendorf, M., Beelen, R. H. & Mulder, W. J. Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease. Expert Rev. Mol. Diagnostics13, 576–580 (2013).
Wu, M. et al. The effect of interstitial pressure on therapeutic agent transport: coupling with the tumor blood and lymphatic vascular systems. J.Theor. Biol.335, 194–207 (2014).
Wijeratne, P. A. & Vavourakis, V. A quantitative in silico platform for simulating cytotoxic and nanoparticle drug delivery to solid tumours. Interface Focus9, 20180063 (2019).
Frieboes, H. B., Wu, M., Lowengrub, J., Decuzzi, P. & Cristini, V. A computational model for predicting nanoparticle accumulation in tumor vasculature. PLoS ONE8, 1–11 (2013).
Hauert, S., Berman, S., Nagpal, R. & Bhatia, S. N. A computational framework for identifying design guidelines to increase the penetration of targeted nanoparticles into tumors. Nano Today8, 566–576 (2013).
Chamseddine, I. M., Frieboes, H. B. & Kokkolaras, M. Design optimization of tumor vasculature-bound nanoparticles. Sci. Rep.8, 17768 (2018).
Thurber, G. M. & Weissleder, R. A systems approach for tumor pharmacokinetics. PLoS ONE6, e24696 (2011).
Cilliers, C., Guo, H., Liao, J., Christodolu, N. & Thurber, G. M. Multiscale modeling of antibody-drug conjugates: Connecting tissue and cellular distribution to whole animal pharmacokinetics and potential implications for efficacy. The AAPS J.18, 1117–1130 (2016).
Liu, J. et al. Design of nanocarriers based on complex biological barriers in vivo for tumor therapy. Nano Today15, 56–90 (2017).
Daum, N., Tscheka, C., Neumeyer, A. & Schneider, M. Novel approaches for drug delivery systems in nanomedicine: Effects of particle design and shape. Wiley Interdisciplinary Rev.: Nanomed. Nanobiotechnol.4, 52–65 (2012).
Anselmo, A. C. et al. Elasticity of nanoparticles influences their blood circulation, phagocytosis, endocytosis, and targeting. ACS Nano9, 3169–3177 (2015).
Bao, G. et al. USNCTAM perspectives on mechanics in medicine. J. Roy. Soc. Interface11, 20140301 (2014).
Zhang, S., Li, J., Lykotrafitis, G., Bao, G. & Suresh, S. Size-dependent endocytosis of nanoparticles. Adv. Mater.21, 419–424 (2009).
Yue, T. & Zhang, X. Cooperative effect in receptor-mediated endocytosis of multiple nanoparticles. ACS Nano6, 3196–3205 (2012).
Stewart, M. P., Lorenz, A., Dahlman, J. & Sahay, G. Challenges in carrier-mediated intracellular delivery: moving beyond endosomal barriers. Wiley Interdisciplinary Rev.: Nanomed. Nanobiotechnol.8, 465–478 (2016).
Martens, T. F., Remaut, K., Demeester, J., De Smedt, S. C. & Braeckmans, K. Intracellular delivery of nanomaterials: How to catch endosomal escape in the act. Nano Today9, 344–364 (2014).
Chiu, Y.-L. et al. The characteristics, cellular uptake and intracellular trafficking of nanoparticles made of hydrophobically-modified chitosan. J. Control. Release146, 152–159 (2010).
Chithrani, B. D. & Chan, W. C. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett.7, 1542–1550 (2007).
Pitt-Francis, J. et al. Chaste: a test-driven approach to software development for biological modelling. Comput. Phys. Commun.180, 2452–2471 (2009).
Winner, K. R. et al. Spatial modeling of drug delivery routes for treatment of disseminated ovarian cancer. Cancer Res.76, 1320–1334 (2016).
Li, J. F. & Lowengrub, J. The effects of cell compressibility, motility and contact inhibition on the growth of tumor cell clusters using the Cellular Potts Model. J. Theor. Biol.343, 79–91 (2014).
Michalski, P. J. & Loew, L. M. SpringSaLaD: a spatial, particle-based biochemical simulation platform with excluded volume. Biophys. J.110, 523–529 (2016).
Ghaffarizadeh, A., Heiland, R., Friedman, S. H., Mumenthaler, S. M. & Macklin, P. PhysiCell: an open source physics-based cell simulator for 3-D multicellular systems. PLoS Comput. Biol.14, e1005991 (2018).
Ghaffarizadeh, A., Friedman, S. H. & MacKlin, P. BioFVM: an efficient, parallelized diffusive transport solver for 3-D biological simulations. Bioinformatics32, 1256–1258 (2016).
Juarez, E. F., Garri, C., Ghaffarizadeh, A., Macklin, P. & Kani, K. Quantification of cancer cell migration with an integrated experimental-computational pipeline. F1000Research7, 1296 (2018).
Letort, G. et al. PhysiBoSS: a multi-scale agent-based modelling framework integrating physical dimension and cell signalling. Bioinformatics35, 1188–1196 (2019).
Andrews, S. S., Addy, N. J., Brent, R. & Arkin, A. P. Detailed simulations of cell biology with Smoldyn 2.1. PLoS Comput. Biol.6, e1000705 (2010).
Hepburn, I., Chen, W., Wils, S. & De Schutter, E. STEPS: efficient simulation of stochastic reaction-diffusion models in realistic morphologies. BMC Syst. Biol.6, 36 (2012).
Chen, W. & De Schutter, E. Parallel STEPS: large scale stochastic spatial reaction-diffusion simulation with high performance computers. Frontiers Neuroinform.11, 1–15 (2017).
Cummings, P. T. & Gilmer, J. B. Open-source molecular modeling software in chemical engineering. Curr. Opin. Chem. Eng.23, 99–105 (2019).
Schmidt, J., Marques, M. R., Botti, S. & Marques, M. A. Recent advances and applications of machine learning in solid-state materials science. npj Comput. Mater.5, 1–36 (2019).
Alber, M. et al. Integrating machine learning and multiscale modeling-perspectives, challenges, and opportunities in the biological, biomedical, and behavioral sciences. npj Digital Med.2, 1–11 (2019).
Bishop, C. M. Pattern Recognition and Machine Learning (springer, 2006).
Alpaydin, E. Introduction to Machine Learning (MIT press, 2020).
Asadi, H., Rostamizadeh, K., Salari, D. & Hamidi, M. Preparation of biodegradable nanoparticles of tri-block pla–peg–pla copolymer and determination of factors controlling the particle size using artificial neural network. J. Microencapsulation28, 406–416 (2011).
Shalaby, K. S. et al. Determination of factors controlling the particle size and entrapment efficiency of noscapine in peg/pla nanoparticles using artificial neural networks. Int. J. Nanomed.9, 4953 (2014).
Liu, R. et al. Classification nanosar development for cytotoxicity of metal oxide nanoparticles. Small7, 1118–1126 (2011).
Hataminia, F., Noroozi, Z. & Eslam, H. M. Investigation of iron oxide nanoparticle cytotoxicity in relation to kidney cells: a mathematical modeling of data mining. Toxicol. in Vitro59, 197–203 (2019).
Labouta, H. I., Asgarian, N., Rinker, K. & Cramb, D. T. Meta-analysis of nanoparticle cytotoxicity via data-mining the literature. ACS Nano13, 1583–1594 (2019).
Findlay, M. R., Freitas, D. N., Mobed-Miremadi, M. & Wheeler, K. E. Machine learning provides predictive analysis into silver nanoparticle protein corona formation from physicochemical properties. Environ. Sci.: Nano5, 64–71 (2018).
Jones, D. E., Ghandehari, H. & Facelli, J. C. A review of the applications of data mining and machine learning for the prediction of biomedical properties of nanoparticles. Comput. Methods Programs Biomed.132, 93–103 (2016).
Sason, H. & Shamay, Y. Nanoinformatics in drug delivery. Israel J. Chem. https://doi.org/10.1002/ijch.201900042 (2019).
Sutton, R. S. & Barto, A. G. Reinforcement Learning: An Introduction (MIT press, 2018).
Jin, Y. Surrogate-assisted evolutionary computation: recent advances and future challenges. Swarm Evolut. Comput.1, 61–70 (2011).
Zhao, Y., Kosorok, M. R. & Zeng, D. Reinforcement learning design for cancer clinical trials. Statistics Med.28, 3294–3315 (2009).
Warmuth, M. K. et al. Active learning with support vector machines in the drug discovery process. J. Chem. Inform. Comput. Sci.43, 667–673 (2003).
Yamankurt, G. et al. Exploration of the nanomedicine-design space with high-throughput screening and machine learning. Nature Biomed. Eng.3, 318–327 (2019).
Parvinian, B. et al. Credibility evidence for computational patient models used in the development of physiological closed-loop controlled devices for critical care medicine. Frontiers Physiol.10, 220 (2019).
Morrison, T. M. et al. Assessing computational model credibility using a risk-based framework: application to hemolysis in centrifugal blood pumps. ASAIO J.65, 349 (2019).
Software as a Medical Device (SaMD): Key Definitions (2013). Available at: http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-131209-samd-key-definitions-140901.pdf.
Software as a Medical Device- (SaMD): Possible Framework for Risk Categorization and Corresponding Considerations (2014). Available at: http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-140918-samd-framework-risk-categorization-141013.pdf.
Software as a Medical Device- (SaMD): Application of Quality Management Systems. (2014). Available at: http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-151002-samd-qms.pdf.
Software as a Medical Device- (SaMD): Clinical Evaluation (2017). Available at: http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-170921-samd-n41-clinical-evaluation_1.pdf.
Proposed regulatory framework for modifications to artificial intelligence/machine learning (AI/ML)-based software as a medical device (SaMD) (2019). Available at: https://www.fda.gov/media/122535/download.
Weis, J. A. et al. Predicting the response of breast cancer to neoadjuvant therapy using a mechanically coupled reaction-diffusion model. Cancer Res.10, 4333–4347 (2015).
Macklin, P., Edgerton, M. E., Thompson, A. M. & Cristini, V. Patient-calibrated agent-based modelling of ductal carcinoma in situ (DCIS): From microscopic measurements to macroscopic predictions of clinical progression. J. Theor. Biol.301, 122–140 (2012).
Korsunsky, I. et al. Systems biology of cancer: a challenging expedition for clinical and quantitative biologists. Frontiers Bioeng. Biotechnol.2, 27 (2014).
Faratian, D., Bown, J. L., Smith, V. A., Langdon, S. P. & Harrison, D. J. Cancer Systems Biology 245–263 (Humana Press, Totowa, NJ, 2010).
Werner, H. M., Mills, G. B. & Ram, P. T. Cancer systems biology: a peek into the future of patient care? Nat. Rev. Clin. Oncol.11, 167–176 (2014).
Kim, M. Y. et al. Tumor self-seeding by circulating cancer cells. Cell139, 1315–1326 (2009).
Koutsoukas, A. et al. From in silico target prediction to multi-target drug design: current databases, methods and applications. J. Proteomics74, 254–2574 (2011).
Macklin, P. et al. Progress Towards Computational 3-D Multicellular Systems Biology 225–246 (Springer International Publishing, 2016).
Rockne, R. C. et al. The 2019 mathematical oncology roadmap. Physical Biology16, 041005 (2019).